Looking beyond short-term turmoil, Syngene is investing for the future
These are transitional times for Syngene, the Bengaluru, India-headquartered contract research, development, and manufacturing organisation (CRDMO). It already has an …
Post
-
-
ERS 2026: obesity, an independent obstruction to biologic-treated asthma
On 7 September at the European Respiratory Society (ERS) 2026 Annual Meeting, investigators from the University of Siena presented their …
-
Gilead and PAHO agree to expedite lenacapavir access for HIV prevention
Gilead Sciences and the Pan American Health Organization (PAHO) have signed an agreement to expedite access to the company’s twice-yearly …
-
Eli Lilly and QurCan sign genetic medicine deal
Eli Lilly and Company and QurCan Therapeutics have signed an exclusive research and collaboration agreement to develop genetic medicine therapeutics …
-
Electra targets $342m IPO to fund hyperinflammatory syndrome drug’s pivotal trials
Electra Therapeutics has unveiled that it plans to raise up to $341.9m in an initial public offering (IPO), with the …
-
Electra targets $342m IPO to fund hyperinflammatory syndrome drug’s pivotal trials
Electra Therapeutics has unveiled that it plans to raise up to $341.9m in an initial public offering (IPO), with the …
-
Agentic AI trust gap slowing healthcare provider adoption, survey reveals
A new survey from digital healthcare security specialist Imprivata has revealed that, while artificial intelligence (AI) is now becoming commonplace …
-
GSK bolsters oncology pipeline with $750m Chimagen TCE deal
GSK has secured the rights to Chimagen Biosciences’ trispecific T-cell engager (TCE) for multiple myeloma, signalling the big pharma company’s …
-
Definium tees up regulatory submission for psychedelic on Phase III hat trick
Definium Therapeutics has drawn up plans to submit a New Drug Application (NDA) to US regulators for its psychedelic medicine, …
-
Cheplapharm to take over 20 medicines and three sites from Sanofi
Cheplapharm has entered a strategic partnership to take over a portfolio of 20 mature medicines, along with three manufacturing facilities …
-
FDA reduces monitoring time for Amgen’s Imdelltra infusions
The US Food and Drug Administration (FDA) has approved an update to the prescribing information for Amgen’s Imdelltra (tarlatamab-dlle), reducing …
-
No more Nordisk: Novo’s latest trim is in its name
When Mike Doustdar joined Novo Nordisk as CEO, he emphasised corporate evolution. Now, a year later, he has delivered a …
-
Pressure intensifies on Novartis as bolt-on deal strategy faces major test
Novartis is facing scrutiny towards its merger and acquisition (M&A) strategy after trial setbacks have rocked investors’ confidence in its …
-
Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval
The US Food and Drug Administration (FDA) approved Scholar Rock’s rare neuromuscular disease therapy, Isemblyd (apitegromab), making it the first …
-
The rare disease revolution: The state of play for CGTs in orphan diseases
Rare diseases are chronic conditions that affect between 3.5% and 5.9% of the global population. About 80% of rare diseases …
